Viimeisimmät artikkelit
- Desentum to present at the 2026 EAACI annual congress in Istanbul this week
- Summons to the Annual General Meeting of Desentum Oy
- Desentum’s 18 M€ share issue from private investors and family offices breaks a record for unlisted growth companies in Finland
- New scientific discovery about the molecular mechanism of allergic reaction sheds light on the severity of peanut allergy
- Enrolment completed in Phase 2 clinical study with DM-101PX, a novel immunotherapy for treating birch pollen allergy
Viimeisimmät kommentit
No comments to show.